The next chapter in the incredible story of a would-be fighter who has captured the professional boxing world’s attention will unfold this Sunday, October 17, in Lagos, Nigeria, as, with some help from World Heavyweight Champion Tyson Fury and UK-based CBD manufacturers Brains Bioceutical, 20-year-old Chibuike ‘Africa Fury’ Ogbuaguairy, the real-life boxing fairytale, will make his long-awaited professional debut.
Africa Fury, who started gaining prominence a couple years ago by posting viral videos that depict him training alongside other fistic hopefuls at a less-than-ideal outdoor gym on an unpaved city street in Lagos, will face Nigerian countryman Gbenga Samson in a heavyweight four-rounder at the Beats and Bites Palace Hotel.
It’s just the latest chapter in an incredible story that begins with a teenaged Ogbuaguairy being invited by a friend to train at the “boxing gym” and instantly falling in love with the sport. Soon after, as a way to maintain motivation in a challenging environment, Ogbuaguairy began posting his training experiences to his Instagram. They quickly caught the attention of Tyson Fury, currently the undefeated lineal and WBC Heavyweight King, who reached out to the young hopeful with, first, advice and messages of encouragement and then a large quantity of training equipment and ‘The Gypsy King’ official apparel for the entire gym.
“I feel like I’m blessed,” said an excited Ogbuaguairy. “It has meant a lot. Every time I wake up and I don’t want to train, I still do train because people are waiting for me to do well in boxing. I’m grateful for that.”
Frequent supporters and sponsors of boxing around the world, Brains Bioceutical a global leader in plant-based pharmaceutical, wellness, and veterinary cannabidiol (CBD) active pharmaceutical ingredient (API), also got onboard the Africa Fury train quite early in his development and made a commitment to help.
Brains Bioceutical Corp., CEO & Chairman Ricky Brar says thrilled to be part of helping the young African slugger reach his dreams.
“Brains is very proud to be assisting this young man,” said Brar. “I’ve always admired those bold enough to go for their dreams, no matter how unlikely or difficult. Africa Fury is a testament to those who strive for what they want and we are delighted to be part of his journey. Its’ a feel-good story all around.”
Calling his jab his best punch that he uses to set everything else up, the 6’ 4” and 240-lb Ogbuaguairy says his pro debut is just the start of the story.
“I want to be a world champion,” added Ogbuaguairy. “It’s my dream. It’ll take a lot of hard work to get there, so I’ll make a lot of sacrifices and stay ready for what’s coming. This is a great honor and I’m very grateful for everything everyone has done for me. They believe I will be world champion and they see something in me. I’m getting better and ready to get in the game and start my career. I really appreciate their support and I hope to make them proud.”
The Brains Bioceutical team say they are hoping to bring Africa Fury to North America soon to train at their state-of-the-art indoor training facility.
For more information on Africa Fury visit his Instagram page HERE.
To purchase Gypsy King official Tyson Fury merchandise, click HERE.
ABOUT BRAINS BIOCEUTICAL CORP.
Brains Bioceutical Corp. is a leader in EU-GMP-certified production of naturally sourced active pharmaceutical ingredients (APIs) for the pharmaceutical and nutraceutical industries. Brains Bioceutical is one of the only natural plant-based cannabinoid active pharmaceutical ingredient (API) manufacturers in commercial production today and is involved in academic and clinical trials across the globe. Brains’ Senior Management Team is comprised of a rare hybrid of pharmaceutical and consumer goods executives-having held C-suite and other senior positions with companies such as GW Pharma, Merck, Danone, Earthbound Farms, International Herbs, Cascadia Specialties and The Royal Navy. Brains’ wholly owned subsidiary in the UK, BSPG Laboratories, is one of only a few companies that has the commercial capability and EU-GMDP certification to produce CBD API.
CAUTIONARY STATEMENT:
This news release contains forward looking statements or forward-looking information (“forward-looking statements”) within the meaning of securities laws. Often, but not always, forward looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. All statements, other than statements of historical fact, in this news release are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance are not statements of historical fact and may be forward-looking statements. Risks, uncertainties and other factors involved with forward-looking statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements in this news release are reasonable, there can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
SOURCE Brains Bioceutical
For further information: Brains Bioceutical Corp., Vancouver, BC, Canada,
1-855-927-2476, BrainsBio.com; [email protected].
